The investigational fungal Cyp51 inhibitor VT-1129 demonstrates potent in vitro activity against cryptococcus neoformans and cryptococcus gattii

Shawn R. Lockhart, Annette W. Fothergill, Naureen Iqbal, Carol B. Bolden, Nina T. Grossman, Edward P. Garvey, Stephen R. Brand, William J. Hoekstra, Robert J. Schotzinger, Elizabeth Ottinger, Thomas F Patterson, Nathan Wiederhold

Research output: Contribution to journalArticle

36 Scopus citations

Abstract

The in vitro activities of the novel fungal Cyp51 inhibitor VT-1129 were evaluated against a large panel of Cryptococcus neoformans and Cryptococcus gattii isolates. VT-1129 demonstrated potent activities against both Cryptococcus species as demonstrated by low MIC50and MIC90values. For C. gattii, the in vitro potency was maintained against all genotypes. In addition, significantly lower geometric mean MICs were observed for VT-1129 than for fluconazole against C. neoformans, including isolates with reduced fluconazole susceptibility.

Original languageEnglish (US)
Pages (from-to)2528-2531
Number of pages4
JournalAntimicrobial Agents and Chemotherapy
Volume60
Issue number4
DOIs
StatePublished - Apr 1 2016

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Infectious Diseases

Fingerprint Dive into the research topics of 'The investigational fungal Cyp51 inhibitor VT-1129 demonstrates potent in vitro activity against cryptococcus neoformans and cryptococcus gattii'. Together they form a unique fingerprint.

  • Cite this

    Lockhart, S. R., Fothergill, A. W., Iqbal, N., Bolden, C. B., Grossman, N. T., Garvey, E. P., Brand, S. R., Hoekstra, W. J., Schotzinger, R. J., Ottinger, E., Patterson, T. F., & Wiederhold, N. (2016). The investigational fungal Cyp51 inhibitor VT-1129 demonstrates potent in vitro activity against cryptococcus neoformans and cryptococcus gattii. Antimicrobial Agents and Chemotherapy, 60(4), 2528-2531. https://doi.org/10.1128/AAC.02770-15